News story

Teva levothyroxine tablets: re-entry to market and introduction of new tablet strengths

Following extensive changes to the formulation and manufacture of levothyroxine tablets by Teva, the Commission on Human Medicines (CHM) is now reassured that Teva has demonstrated an acceptable level of efficacy and safety to allow their levothyroxine tablets to re-enter the market. Additional tablet strengths have also been introduced, to improve precision of dosing.